Ethan B. Ludmir, MD, explains the rationale for moving radiation into the neoadjuvant setting for borderline resectable ...
Ola Landgren, MD, PhD, discusses how MRD-driven strategies may eliminate the transplant-eligible vs transplant-ineligible ...
Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG ...
Although not yet statistically significant, the difference in progression-free survival (PFS) outcomes continues to grow with ...
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
Ludmir, MD, discussed neoadjuvant radiation, advanced treatment techniques, the HYPERION CCA trial, and lirafugratinib in ...
No new safety signals were observed with the daratumumab regimen after an additional 3 years of follow-up in the phase 3 ...
TriNav Advance is the fourth FDA-cleared PEDD device in TriSalus’s portfolio, joining the TriNav Infusion System and TriNav ...
The FDA has approved lirafugratinib (Lyrfigtu), an investigational oral FGFR2 inhibitor, as a treatment for patients with ...
Elizabeth Thompson, MD, discusses pediatric cancer, proton therapy, and her work as a peer reviewer for CURiE. In an ...
Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small ...
Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results